Abbott Lingo

Lingo is Abbott's first consumer "biowearable" — a glucose sensor sold for general health and wellness, not for managing diabetes. It is a small round sensor worn on the back of the upper arm that reads glucose in the fluid just under your skin and streams a value every minute to the Lingo coaching app on your phone.¹ We cover it to map the wellness edge of the CGM landscape; almost everything about it makes it less suitable for type 1 than a prescription sensor, not more.

What it is built from. Under the hood Lingo is not the flagship Libre 3 — its hardware and clearance are based on the older FreeStyle Libre 2 (predicate K222447).¹ The FDA cleared it in the US on 10 June 2024 as an over-the-counter iCGM for people 18 and older who are not on insulin; in the UK it launched earlier, on 9 January 2024, sold purely as a non-medical wellness device.²³ Abbott is explicit that Lingo is "not intended for diagnosis of diseases, including diabetes."⁴

Accuracy. Abbott re-analysed the Libre 2 pivotal study to support Lingo; overall accuracy is a MARD (mean absolute relative difference — lower is better) of roughly 9.2–9.3%, modestly worse than the Libre 3 family.¹ Per glucose range the MARD was 9.9% below 70 mg/dL, 9.7% at 70–180, and 8.1% above 180.¹ The catch that matters most for T1D: Lingo only reports glucose from 55 to 200 mg/dL — a deliberately truncated range. It will not show you a true severe low or a high; the Libre 2 it is based on reads 40–400 mg/dL.¹

Wear, warm-up, calibration. Up to 14 days per sensor, ~60-minute warm-up, factory-calibrated with no fingersticks.¹ Reliability is unimpressive: in testing only 77.1% of sensors lasted to the final day — roughly one in five ended early.¹

Alerts — the dealbreaker. Lingo has no glucose alarms at all, and no trend arrows. The FDA's own comparison table lists alarms, trend arrows and interoperability as features of the Libre 2 predicate that Lingo strips out ("Device features to manage diabetes: None").¹ It cannot warn you of a low — disqualifying for anyone on insulin.

What it connects to. Nothing useful for T1D. The system "is not intended to be used in conjunction with insulin devices such as insulin pens and Automated Insulin Dosing (AID) systems," and it pairs only with the Lingo coaching app — no receiver, no pump, no DIY loop.¹ The app launched iOS-only and added Android in December 2025.⁵ Instead of dosing tools it offers a "Lingo Count" spike metric, meal/exercise logging, and habit challenges.⁴

Ketones. None — glucose only.¹

Who it's for. Adults 18+ not on insulin who want to see how food, exercise and sleep move their glucose — wellness users, not people with type 1.² It is explicitly not for insulin users, dialysis, or critical illness, and high-dose vitamin C can falsely raise readings.¹

Access & cost. No prescription, but cash-pay only and not reimbursed. Both US and UK offer tiered plans priced by the number of sensors, from a single two-week sensor up to a multi-sensor program — a moderate out-of-pocket cost overall.⁴⁶³ HSA/FSA-eligible in the US, sold online (hellolingo.com) and at Walgreens; available only in the US and UK.⁶

What's coming. Abbott's roadmap for Lingo is consumer reach, not diabetes capability — retail expansion (Amazon, Walmart) and the move to Android in late 2025.⁵ For T1D, the relevant Abbott line is the prescription FreeStyle Libre 3 Plus and its growing AID ecosystem, tracked separately on this site — not Lingo.

References

1. U.S. Food & Drug Administration. 510(k) K233655 — Lingo Glucose System, Substantial Equivalence Decision Summary (29 May 2024). https://www.accessdata.fda.gov/cdrh_docs/reviews/K233655.pdf ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

2. Abbott. Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems. PR Newswire (10 June 2024). https://www.prnewswire.com/news-releases/abbott-receives-us-fda-clearance-for-two-new-over-the-counter-continuous-glucose-monitoring-systems-302167780.html ↩ ↩²

3. Abbott. Abbott introduces first ever consumer biowearable, Lingo, set to re-energise the nation. Abbott UK (9 Jan 2024). https://www.abbott.co.uk/media-center/news/Abbott-introduces-first-ever-consumer-biowearable-Lingo-TM-set-to-re-energise-the-nation.html ↩ ↩²

4. Abbott. Abbott's Lingo Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. Abbott Newsroom (5 Sept 2024). https://abbott.mediaroom.com/2024-09-05-Abbotts-Lingo-TM-Continuous-Glucose-Monitor-for-Health-and-Wellness-Now-Available-in-the-U-S ↩ ↩² ↩³

5. Hale C. Abbott expands Lingo OTC CGM to Android devices. Drug Delivery Business News (8 Dec 2025). https://www.drugdeliverybusiness.com/abbott-expands-lingo-otc-cgm-to-android-devices/ ↩ ↩²

6. Reuter E. Abbott debuts Lingo over-the-counter CGM in the US. MedTech Dive (6 Sept 2024). https://www.medtechdive.com/news/abbott-lingo-rollout-us-otc-cgm/726330/ ↩ ↩²